Hydrocortisone Cypionate

Summary

Hydrocortisone Cypionate (CHEMBL1549) is an approved small molecule; indicated across 1 condition including chronic primary adrenal insufficiency.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 5
• Chemistry: 486.6 Da · C29H42O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1549
Name	Hydrocortisone Cypionate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	223253
Molecular formula	C29H42O6
Molecular weight	486.6
InChIKey	DLVOSEUFIRPIRM-KAQKJVHQSA-N

SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC5CCCC5)O)C)O

IUPAC name: [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 3-cyclopentylpropanoate

Also known as: Cortef, Hydrocortisone cipionate, Hydrocortisone cypionate, NSC-10721, HYDROCORTISONE CYPIONATE, SID75847

Patent coverage: 1,403 distinct patent families (5,075 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic primary adrenal insufficiency	2	MONDO:0015129	MONDO:0015129

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2/PHASE3	1
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01063569	PHASE2/PHASE3	COMPLETED	Glucocorticoid Treatment in Addison’s Disease
NCT05063994	PHASE3	COMPLETED	Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
NCT00519818	PHASE1/PHASE2	COMPLETED	Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
NCT01840189	PHASE2	TERMINATED	Continuous Subcutaneous Hydrocortisone Infusion In Addison’s Disease and Type 1 Diabetes
NCT02096510	PHASE1/PHASE2	COMPLETED	Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).